Results 181 to 190 of about 432,036 (307)

Can Photoacoustic Imaging Provide a Sensitive Marker for Early Detection of Diabetic Nephropathy. [PDF]

J Biophotonics
Qiu T, Cao J, Yang X, Luo Y, Wang H, Ling W.   +5 more
europepmc   +1 more source

Oral Butyrate Reduces Progression of Kidney Damage in an L‐NAME‐Induced Diabetic Kidney Disease Mouse Model

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Diabetic kidney disease (DKD) is one of the main causes of kidney failure worldwide. Interestingly, patients affected by DKD are characterised by a low abundance of gut bacteria producing short fatty acids including butyrate, which is suggested to play a role in the decline of renal function.
Maria Novella Nicese, Angela Koudijs, Reshma Lalai, Cristina Avramut, Rico J. E. Derks, Elena Sánchez‐López, Martin Giera, Amanda C. M. Pronk, Artemiy Kovynev, Sander Kooijman, Patrick C. N. Rensen, Roel Bijkerk, Bernard M. van den Berg, Joris I. Rotmans   +13 more
wiley   +1 more source

Mechanism of microcirculation disturbance in diabetic nephropathy: A review. [PDF]

Medicine (Baltimore)
Tang W, Liu H, Li X, Deng S, Gao C.
europepmc   +1 more source

Person‐Reported and Continuous Glucose Monitoring (CGM) Recorded Hypoglycaemia in People With Insulin‐Treated Type 2 Diabetes and Mild to Moderate Chronic Kidney Disease; Post Hoc Analysis From the Hypo‐METRICS Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background and Aims People with diabetes and chronic kidney disease (CKD) may be at increased risk of iatrogenic hypoglycaemia. We compared rates of sensor‐detected (SDH) and person‐reported hypoglycaemia (PRH) in people with insulin‐treated Type 2 diabetes (T2D) with and without CKD in the Hypo‐METRICS study.
Julie M. B. Brøsen, Daniel Malmsiø, Patrick Divilly, Gilberte Martine‐Edith, Natalie Zaremba, Namam Ali, Rory J. McCrimmon, Simon Heller, Mark Evans, Bastiaan de Galan, Julia K. Mader, Eric Renard, Allan A. Vaag, Pratik Choudhary, Ulrik Pedersen‐Bjergaard, on behalf of the HypoRESOLVE Consortium, Andrew Pernet, Amy Aldridge, Marcia Henderson‐Wilson, Pernille Banck‐Petersen, Rikke Carstensen, Charlotte Hansen, Sharon Caunt, Sue Hudson, Chloe Husband, Fahad Arshad, Anne Farret, Anne‐Marie Marteil‐Oudrer, Manal Shbat, Lisa Crespy, Jenny Constanza Thibout, Anja Rasing, Jesper Walburgh Schimidt, Daniel Loewenstein, Renate Huijsmans, Pieter Drijver, Daniel Chapman, Jane Kennet, Anna Barnett, Jackie Lindsay   +39 more
wiley   +1 more source

Translational advances in diabetic nephropathy management: integrating nanoformulation-based drug delivery systems. [PDF]

Front Med Technol
Ansari MD, Vishwakarma A, Quamuddin M, Aggarwal M, Khan H, Abd Jalil MF, Mahmood S, Wali AF, Talath S, El-Tanani M.   +9 more
europepmc   +1 more source

Transcriptomic and genetic evidence highlights EHHADH in a FUNDC1-associated mitochondrial network in diabetic nephropathy. [PDF]

Metabol Open
Chen Y, Ying D, Guo X, Wang S, Liu W, Wang S, Kuang N, Li J, Chen N.   +8 more
europepmc   +1 more source

Initiation of SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims‐Based Active‐Comparator New‐User Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To examine the association between initiation of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and risk of incident depression compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitors among adults with newly diagnosed Type 2 diabetes receiving metformin.
Sangwoo Park, Seogsong Jeong, Hye Jun Kim, Dae Ho Lee, Soo Jung Choi, Sang Min Park   +5 more
wiley   +1 more source

Tau beyond the Brain: Endoplasmic Reticulum Stress and Tau Phosphorylation as Emerging Drivers of Diabetic Nephropathy. [PDF]

Diabetes Metab J
Kim NY, Oh CM.
europepmc   +1 more source

Diabetic Infantilism with Diabetic Nephropathy [PDF]

Proceedings of the Royal Society of Medicine, 1952
openaire   +2 more sources

Real‐World Evidence for Existing Anti‐Obesity Therapies—The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Obesity is associated with substantial cardiometabolic and psychosocial morbidity. Although randomized controlled trials demonstrate the efficacy of anti‐obesity therapies, outcomes in real‐world practice may be attenuated due to limited access, tolerability, adherence and insufficient long‐term support.
Sameer Kassem
wiley   +1 more source